SE9904424D0 - Use of interleukin-6 in combination with leptin in the treatment of obesity - Google Patents

Use of interleukin-6 in combination with leptin in the treatment of obesity

Info

Publication number
SE9904424D0
SE9904424D0 SE9904424A SE9904424A SE9904424D0 SE 9904424 D0 SE9904424 D0 SE 9904424D0 SE 9904424 A SE9904424 A SE 9904424A SE 9904424 A SE9904424 A SE 9904424A SE 9904424 D0 SE9904424 D0 SE 9904424D0
Authority
SE
Sweden
Prior art keywords
obesity
interleukin
treatment
leptin
combination
Prior art date
Application number
SE9904424A
Other languages
Swedish (sv)
Inventor
John-Olov Janssson
Ville Wallenius
Original Assignee
Sahltech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9902680A external-priority patent/SE9902680D0/en
Application filed by Sahltech Ab filed Critical Sahltech Ab
Priority to SE9904424A priority Critical patent/SE9904424D0/en
Publication of SE9904424D0 publication Critical patent/SE9904424D0/en
Priority to EP00950167A priority patent/EP1194159A1/en
Priority to PCT/SE2000/001491 priority patent/WO2001003725A1/en
Priority to AU63303/00A priority patent/AU6330300A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Use of a substance that upon administration to a patient will lead to an increased level of an interleukin-6 (IL-6) receptor agonist, preferably IL-6, for the production of a medicinal product for treatment of obesity and/or obesity associated disorders is disclosed. Also a method for treatment of obesity and/or obesity associated disorders wherein a pharmaceutically effective amount of a substance that upon administration to a patient will lead to an increased level of an interleukin-6 receptor agonist is disclosed.
SE9904424A 1999-07-13 1999-12-03 Use of interleukin-6 in combination with leptin in the treatment of obesity SE9904424D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE9904424A SE9904424D0 (en) 1999-07-13 1999-12-03 Use of interleukin-6 in combination with leptin in the treatment of obesity
EP00950167A EP1194159A1 (en) 1999-07-13 2000-07-13 Use of interleukin-6 in treatment of obesity and/or obesity associated disorders
PCT/SE2000/001491 WO2001003725A1 (en) 1999-07-13 2000-07-13 Use of interleukin-6 in treatment of obesity and/or obesity associated disorders
AU63303/00A AU6330300A (en) 1999-07-13 2000-07-13 Use of interleukin-6 in treatment of obesity and/or obesity associated disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902680A SE9902680D0 (en) 1999-07-13 1999-07-13 Use of interleukin-6 in the treatment of obesity and disorders of blood fats
SE9904424A SE9904424D0 (en) 1999-07-13 1999-12-03 Use of interleukin-6 in combination with leptin in the treatment of obesity

Publications (1)

Publication Number Publication Date
SE9904424D0 true SE9904424D0 (en) 1999-12-03

Family

ID=26663620

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9904424A SE9904424D0 (en) 1999-07-13 1999-12-03 Use of interleukin-6 in combination with leptin in the treatment of obesity

Country Status (4)

Country Link
EP (1) EP1194159A1 (en)
AU (1) AU6330300A (en)
SE (1) SE9904424D0 (en)
WO (1) WO2001003725A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129160A1 (en) * 2002-01-09 2003-07-10 John-Olov Jansson Use of Interleukin-6
SE0201689D0 (en) * 2002-06-03 2002-06-03 Sahltech Ab A method for identifying obese IL-6 responsive patients
CN101219208B (en) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 Medicine use of interleukin-22
FR3080533A1 (en) 2018-04-27 2019-11-01 Enterosys USE OF IL-6 FOR THE TREATMENT OF DIABETES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186367A (en) * 1991-08-06 1993-07-27 Toray Ind Inc Therapeutic agent for hyperlipemia
JP2000513564A (en) * 1996-03-01 2000-10-17 アムジエン・インコーポレーテツド Canine OB protein compositions and methods

Also Published As

Publication number Publication date
EP1194159A1 (en) 2002-04-10
AU6330300A (en) 2001-01-30
WO2001003725A1 (en) 2001-01-18

Similar Documents

Publication Publication Date Title
AU2003301190A1 (en) Administration of capsaicinoids
ES2166111T3 (en) USE OF TIAGABINE FOR THE TREATMENT OF SLEEP DISORDERS.
EP0377272A3 (en) Use of nalmefene or naltrexone in the manufacture of a medicament for the treatment of inflammation in an arthritic disease or associated inflammatory diseases
DK0946151T3 (en) Dosage form with increasing dose release
WO2001005763A3 (en) Compounds with activity on muscarinic receptors
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
WO2003077972A8 (en) Implantable drug delivery system
ATE292982T1 (en) ANALGESIC SYNERGY THROUGH SIMULTANEOUS ADMINISTRATION OF SUBANALGESIC DOSES OF A MU-OPIOID ANAGONIST AND A KAPPA-2-OPIOID ANAGONIST
EE200200274A (en) Use of a pyrrolidine acetamide derivative in the manufacture of a medicament for the treatment of disorders of the central nervous system, and a pharmaceutical composition
MXPA04001187A (en) Interleukin-1 receptors in the treatment of diseases.
DE69017654D1 (en) ANALGETIC LOTION TO BE APPLIED ON THE OUTSIDE AND METHOD FOR THE PRODUCTION THEREOF.
SE0002754D0 (en) New pharmaceutical combination formulation and method of treatment with the combination
IT1282353B1 (en) PHARMACEUTICAL COMPOSITION, IN PARTICULAR LIQUID, BY ORAL ADMINISTRATION OF ONDANSETRON AND METHODS FOR ITS PRODUCTION
BR0014912A (en) Treatment of sleep disorders using desloratadine
DK0998287T3 (en) Use of levobupivacaine
NO20101070L (en) Method of dosing a drug, as well as dosage form
BRPI0412430A (en) zot and zonulin receptor agonist polypeptide
SE9902597D0 (en) New use
SE9904424D0 (en) Use of interleukin-6 in combination with leptin in the treatment of obesity
GEP201606538B (en) Preoperative treatment of post operative pain
HUP0204391A2 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
EE200100689A (en) Use of IL6RIL6 Chimera for the preparation of a medicament for the treatment of neurological diseases, and pharmaceutical composition
SE9803732D0 (en) Nicotine treatment for obsessive compulsive disorder
PT942729E (en) UTILIZATION OF NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF STRESSE DISEASES
BRPI0408059A (en) opioid delivery system